Abstracts highlight data pertaining to both Iomab-B and Actimab-A clinical results including the SIERRA Phase 3 trial, dosimetry and machine learning applications for personalized radiotherapy dosing ...
Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and ...
- SNMMI Henry N. Wagner, Jr., Abstract of the Year award represents top selection out of more than 1,500 abstracts accepted for presentation NEW YORK, June 26, 2023 /PRNewswire/ -- Actinium ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results